Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of CRD3874-SI in Advanced/Metastatic Solid Tumors
NCT06021626Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2023
- Primary completion
- Aug 2029
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRD3874 in solid tumor, sarcoma, Merkel cell carcinoma (MCC) and 5 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Objective Response Rate up to 48 weeks. Started Aug 2023; status: recruiting.
02
Drugs
CRD3874
03
Conditions
solid tumorsarcomaMerkel cell carcinoma (MCC)head and neck squamous cell carcinoma (HNSCC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT06021626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021626.